EVerZom secures €10 million to advance exosome-based therapies for inflammatory diseases
French biotechnology company EVerZom has closed a €10 million funding round to support clinical development of its exosome-based therapeutic platform, with lead candidate EVerGel set to enter human trials in 2026 for treatment of complex perianal fistulas in Crohn’s disease.
The Strasbourg-based company announced on 14 October 2025 that the investment round was backed by Capital Grand Est, the European Innovation Council Fund, Sorbonne Venture by Audacia and Aloe Private Equity, Paris Business Angels, the Capital Cell platform, and several family offices.
Clinical programme targets unmet need in Crohn’s disease
EVerGel represents the company’s flagship therapeutic candidate, combining mesenchymal stem cell-derived exosomes with a biocompatible hydrogel matrix. The formulation is designed to deliver sustained local release of exosomes whilst promoting tissue regeneration in perianal fistulas, a severely debilitating complication affecting Crohn’s disease patients.
The therapeutic approach addresses a significant clinical gap following the December 2024 withdrawal of Alofisel from the European market. The Takeda-marketed stem cell therapy was discontinued after unsuccessful clinical development in the United States, leaving more than 60% of patients without effective treatment options.
Preclinical efficacy data for EVerGel demonstrated complete healing in 87.5% of cases at four weeks in animal models, compared with 12.5% in control groups. The company expects to initiate first-in-human trials during 2026, targeting a patient population of nearly 2 million individuals globally affected by Crohn’s disease.
Platform expansion across therapeutic areas
Beyond the Crohn’s disease programme, EVerZom is developing Eviv, a preclinical candidate for acute-on-chronic liver failure, a severe hepatic condition where transplantation remains the primary intervention. The company’s strategy encompasses expansion into dermatology, cosmetics,and veterinary applications, alongside pharmaceutical partnerships for co-development of exosome-based therapeutics.
“Our ambition is to bring the therapeutic potential of exosomes to patients suffering from diseases with high unmet medical need, where quality of life is severely impaired,” said Jeanne Volatron, co-founder and CEO of EVerZom. “Our priority is to achieve a first clinical proof-of-concept in Crohn’s perianal fistula and to establish the foundations of an industrial and partnership platform capable of driving the emergence of a new therapeutic class.”
Manufacturing scale-up supported by France 2030
The funding will support expansion of EVerZom’s GMP-compliant exosome bioproduction platform, with manufacturing capacity planned to scale to 50 litres. This industrialisation programme received additional support through a €3 million grant from Bpifrance in June 2025 under the France 2030 “Biotherapies and Bioproduction of Innovative Therapies” initiative.
Founded in 2019, EVerZom has established a proprietary technology platform spanning cell selection, high-yield exosome production, modification, and formulation processes. The platform is protected by multiple patents and has received validation through the EIC Accelerator programme.
Virginie Miath, investment director at Capital Grand Est, noted: “EVerZom embodies the new generation of European biotechs: a breakthrough technology, a platform vision, and a strategic approach combining clinical validation, industrialisation, and market expansion.”
For more information, visit: https://everzom.com
